Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - capmatinibum - compresse rivestite con film - capmatinibum 150 mg ut capmatinibi hydrochloridum monohydricum, cellulosum microcristallinum, mannitolum, crospovidonum, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, natrii laurilsulfas corresp. natrium 0.12 mg, Überzug: hypromellosum, e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - capmatinibum - compresse rivestite con film - capmatinibum 200 mg ut capmatinibi hydrochloridum monohydricum, cellulosum microcristallinum, mannitolum, crospovidonum, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, natrii laurilsulfas corresp. natrium 0.16 mg, Überzug: hypromellosum, e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto. - nicht-kleinzelliges lungenkarzinom - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.